Diclofenac, Silymarin May Prevent Chemo-Induced Hand-Foot Syndrome

The options to depart Israel have been updated as of March 23, 2026, according to a security alert issued by the U.S. Embassy in Jerusalem. While there are no changes to shelter-in-place or embassy operations, the U.S. Government is prepared to assist American citizens who wish to leave the Middle East with updated departure information. This comes amid ongoing monitoring of the situation in the region and a restriction on departures from Israel – currently limited to one flight per hour with a maximum of 50 passengers, starting at 5pm local time.

Preventing Chemotherapy-Induced Hand-Foot Syndrome: New Insights

For individuals undergoing chemotherapy, particularly with capecitabine, a painful side effect known as hand-foot syndrome (HFS) can significantly impact quality of life. New research, published in JAMA Dermatology, suggests readily available over-the-counter treatments may offer a proactive way to mitigate this risk. The study highlights the potential benefits of diclofenac gel and the topical flavonoid silymarin, also known as milk thistle, in preventing HFS.

Hand-foot syndrome, also referred to as palmar-plantar erythrodysesthesia, manifests as tingling, numbness, skin peeling (desquamation), blistering, and even ulceration on the palms of the hands and soles of the feet. It’s a dose-dependent toxicity, meaning the severity often correlates with the amount of chemotherapy administered. Several drugs are associated with HFS, including 5-fluorouracil, capecitabine, liposomal doxorubicin, cytarabine, and docetaxel.

Capecitabine (Xeloda, Hoffmann-LaRoche), frequently used in the treatment of gastrointestinal and breast cancers, is a particularly common culprit, affecting up to half of patients receiving the drug. The discomfort and disruption caused by HFS can necessitate dose reductions, treatment interruptions, or even discontinuation, potentially impacting survival outcomes.

Meta-Analysis Reveals Promising Interventions

Researchers, led by Atul Batra, MD, DM, of the All India Institute of Medical Sciences and the Dr. B.R.A. Institute Rotary Cancer Hospital in New Delhi, India, conducted a meta-analysis of 19 randomized controlled trials. The analysis focused on 17 studies evaluating capecitabine-induced HFS, encompassing 2,192 patients with a median age of 57 years. The primary goal was to determine the effectiveness of various pharmacological strategies in preventing HFS, specifically grade 2 or higher severity.

The study revealed that several medications demonstrated a significant reduction in the incidence of grade 2 or higher HFS compared to placebo. These included topical silymarin (OR = 0.08; 95% CI, 0.01-0.71), diclofenac (OR = 0.23; 95% CI, 0.08-0.62), 400 mg pyridoxine (OR = 0.28; 95% CI, 0.09-0.88), and celecoxib (OR = 0.41; 95%CI, 0.18-0.95).

However, the researchers cautioned that the findings regarding topical silymarin should be interpreted with some reservation due to the small sample size (n = 20) and the relatively wide confidence intervals. “Diclofenac gel is the most evidence-based effective intervention to prevent capecitabine-associated hand-foot syndrome,” Dr. Batra told Healio. “Silymarin appears to be effective; however, further studies are needed to confirm efficacy.”

Further analysis showed that diclofenac (OR = 0.30; 95% CI, 0.13-0.69) and celecoxib (OR = 0.46; 95% CI, 0.22-0.94) also reduced the overall incidence of HFS, while silymarin and 400 mg pyridoxine did not demonstrate a significant effect. Interestingly, mapisal ointment was found to increase the risk of developing HFS threefold (OR = 3.04; 95% CI, 1.07-8.64).

What Does This Indicate for Patients?

The study’s findings suggest that proactive use of diclofenac gel may be a routine preventative measure for patients undergoing capecitabine chemotherapy. While silymarin shows promise, larger and more robust studies are needed to solidify its effectiveness. It’s important to remember that these interventions aim to prevent HFS, and do not constitute treatment for existing symptoms.

Hand-foot syndrome isn’t life-threatening, but it can severely diminish a patient’s quality of life. Preventing or minimizing its severity can allow individuals to continue their cancer treatment regimen with fewer interruptions and a better overall experience.

Understanding the Evidence and Its Limitations

The meta-analysis provides valuable insights, but it’s crucial to acknowledge its limitations. The study primarily focused on capecitabine-induced HFS, and the results may not be generalizable to other chemotherapy drugs associated with the condition. The included studies varied in their methodologies and patient populations, which could introduce some degree of heterogeneity.

The researchers also emphasize the need for further research to assess the efficacy of these interventions in diverse ethnic populations. The current study did not specifically analyze outcomes based on ethnicity, and it’s possible that responses may vary across different groups.

The Path Forward: Future Research and Clinical Practice

Dr. Batra and his colleagues recommend that diclofenac gel be considered for routine use in preventing capecitabine-associated HFS. However, they also highlight the need for ongoing research to refine preventative strategies and address remaining uncertainties. Future studies should focus on larger sample sizes, diverse patient populations, and comparisons of different preventative approaches.

Clinicians should discuss the potential benefits and risks of these interventions with their patients, taking into account individual factors and preferences. Open communication and shared decision-making are essential in optimizing patient care and minimizing the impact of chemotherapy-induced side effects.

For more information:

Atul Batra, MD, DM can be reached on X: @batraatulonc.